NASDAQ:AMLN - Amylin Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.

Receive AMLN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AMLN
CUSIPN/A
Phone+1-858-5522200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Amylin Pharmaceuticals (NASDAQ:AMLN) Frequently Asked Questions

What is Amylin Pharmaceuticals' stock symbol?

Amylin Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLN."

Has Amylin Pharmaceuticals been receiving favorable news coverage?

Media headlines about AMLN stock have been trending positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amylin Pharmaceuticals earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the near term.

What other stocks do shareholders of Amylin Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amylin Pharmaceuticals investors own include aTyr Pharma (LIFE), Alphabet (GOOG), Keurig Green Mountain (GMCR), First Solar (FSLR), EXACT Sciences (EXAS), Booking (BKNG), Arena Pharmaceuticals (ARNA), Ariad Pharmaceuticals (ARIA), Amarin (AMRN) and Aegerion Pharmaceuticals (AEGR).

How do I buy shares of Amylin Pharmaceuticals?

Shares of AMLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amylin Pharmaceuticals' official website?

The official website for Amylin Pharmaceuticals is http://www.amylin.com.

How can I contact Amylin Pharmaceuticals?

Amylin Pharmaceuticals' mailing address is 9360 Towne Centre Dr Ste 110, SAN DIEGO, CA 92121-3030, United States. The biopharmaceutical company can be reached via phone at +1-858-5522200.


MarketBeat Community Rating for Amylin Pharmaceuticals (NASDAQ AMLN)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Amylin Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel